Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4245 Target Snapshot

Estrogen-related receptor gamma · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
391Compounds
132Assays
2Approved Drugs
435.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Estrogen-related receptor gamma shows clinical signal disease relevance led by breast cancer. 2 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P62508. Start with breast cancer, then reuse UniProt P62508 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with breast cancer, then reuse UniProt P62508 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
breast cancer

Estrogen-related receptor gamma shows clinical signal disease relevance led by breast cancer. 2 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with breast cancer because it currently carries clinical signal support. Linked drugs include AFIMOXIFENE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Estrogen-related receptor gamma as ChEMBL target CHEMBL4245, mapped to UniProt P62508. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Estrogen-related receptor gamma
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4245
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P62508
Estrogen-related receptor gamma
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Estrogen-related receptor gamma is the right protein anchor across sources, using UniProt P62508 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why breast cancer is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameEstrogen-related receptor gamma
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP62508
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelEstrogen-related receptor gamma
UniProt AccessionP62508
Component TypeProtein
Sequence Length458 aa

Estrogen-related receptor gamma

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Estrogen-related receptor gamma, mapped to UniProt P62508. Sequence length is 458 aa.

Mapped IDP62508
Review nameEstrogen-related receptor gamma
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

Estrogen-related receptor gamma shows clinical signal disease relevance led by breast cancer. 2 more disease programs remain visible in the same review block.

Clinical signal Phase II
breast cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugAFIMOXIFENE
Clinical signal Phase II
breast ductal carcinoma in situ
1 linked drug · 1 direct · 1 efficacy
Linked drugAFIMOXIFENE
Clinical signal Phase II
mastodynia
1 linked drug · 1 direct · 1 efficacy
Linked drugAFIMOXIFENE
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with breast cancer because it currently carries clinical signal support. Linked drugs include AFIMOXIFENE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasebreast cancer
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

2
Approved
Assay Mix

Activity Type Distribution

IC50280.0
EC50150.0
KD5.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL418971 8.31 IC50 4.91 Preclinical
CHEMBL203472 8.3 IC50 5.0 Preclinical
CHEMBL418971 8.26 Kd 5.5 Preclinical
CHEMBL4436391 8.22 IC50 6.0 Preclinical
CHEMBL2137046 7.96 IC50 11.0 Preclinical
CHEMBL4741828 7.89 IC50 13.0 Preclinical
CHEMBL1402 7.89 IC50 13.0 Preclinical
CHEMBL2137046 7.82 EC50 15.0 Preclinical
CHEMBL4598385 7.77 IC50 17.0 Preclinical
CHEMBL4437929 7.77 IC50 17.0 Preclinical
Distribution

pChEMBL Value Distribution

33
5.0
56
5.5
54
6.0
48
6.5
89
7.0
43
7.5
4
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

TAMOXIFEN
CHEMBL83
Approved 1977
Properties Compare Identifier
DIETHYLSTILBESTROL
CHEMBL411
Approved 1973
Properties Compare Identifier
Assay Landscape

Assay Landscape

132
Total Assays
267
Tested Compounds
3
Assay Types
Binding — 118 assays, 267 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 100 87 6.2
single protein format 18 180 6.8
Functional — 13 assays, 9 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 7 0 —
assay format 6 9 6.5
ADME — 1 assays, 2 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 1 2 7.8

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine